血友病A预防治疗预算影响数据集

数据集获取（Figshare）

• 源站标题：Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy
• DOI：10.6084/m9.figshare.22587155.v2
• 发布日期：2023-04-13
• 文件数：9 个
• 文件总体积：650.89 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Budget_impact_of_prophylactic_treatment_of_rVIII-SingleChain_in_moderate_and_severe_Hemophilia_A_in_Italy/22587155

命令行下载

curl -L -o "Figure S1.tif" "https://ndownloader.figshare.com/files/40099103"
curl -L -o "Figure S2.tif" "https://ndownloader.figshare.com/files/40099106"
curl -L -o "Table S1.docx" "https://ndownloader.figshare.com/files/40099109"
curl -L -o "Table S2.docx" "https://ndownloader.figshare.com/files/40099112"
curl -L -o "Table S3.docx" "https://ndownloader.figshare.com/files/40099115"
curl -L -o "Table S4.docx" "https://ndownloader.figshare.com/files/40099118"
curl -L -o "Table S5.docx" "https://ndownloader.figshare.com/files/40099121"
curl -L -o "Table S6.docx" "https://ndownloader.figshare.com/files/40099124"

文件清单

• Figure S1.tif（245.61 KB）
• Figure S2.tif（242.51 KB）
• Table S1.docx（23.02 KB）
• Table S2.docx（24.39 KB）
• Table S3.docx（23.93 KB）
• Table S4.docx（22.95 KB）
• Table S5.docx（22.83 KB）
• Table S6.docx（22.65 KB）
• Table S7.docx（23.01 KB）

文件总体积 650.89 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

rVIII-SingleChain, a recombinant factor VIII (rFVIII), has demonstrated safety and efficacy in patients with hemophilia A in clinical trials and real-world evidence. This analysis aimed to estimate the potential budget impact of increasing the usage of rVIII-SingleChain for the prophylactic treatment of hemophilia A over 3 years in Italy.
Patients with moderate and severe hemophilia A receiving prophylaxis were included in the analysis. Epidemiological data were obtained from published literature. Mean product consumption and mean annual bleeding rate for rVIII-SingleChain, rFVIIIFc, octocog alfa and BAY 81-8973 were based on pooled real-world data from Italy, Germany and US. A budget impact model has been developed in order to compare two scenarios: a base-case scenario where current rVIII-SingleChain shares are kept constant over 3 years and an alternative scenario where rVIII-SingleChain shares increase by taking from other rFVIII products. Analysis 1 was based on the current Italian list prices and Analysis 2 considered current regional acquisition prices for both scenarios.
Annually, adult patients treated with rVIII-SingleChain prophylaxis are expected to consume 324,589 units per patient, resulting in annual costs of €240,196 per patient. In Analysis 1, comparing the base case (constant market share of 9% rVIII-SingleChain over time) with the alternative scenario (higher rVIII-SingleChain market share and increasing from 15% in the first year to 25% in the third year), the total expenditure for prophylaxis using rFVIII products is expected to decrease by €1.4 million in Year 1, by €3.1 million in Year 2 and by €5.4 million in Year 3. In Analysis 2 based on regional prices, the results remained consistent.
This analysis suggests that increasing utilization of rVIII-SingleChain in hemophilia A patients may lead to cost savings as a result of reduced consumption with uncompromised efficacy in bleed protection.
Why was the study done?
Hemophilia A is a rare inherited bleeding disorder. People with severe hemophilia are more likely to bleed compared to people without hemophilia and bleeds can occur spontaneously or in response to trauma. Patients are tre

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.22587155.v2（source: https://tandf.figshare.com/articles/dataset/Budget_impact_of_prophylactic_treatment_of_rVIII-SingleChain_in_moderate_and_severe_Hemophilia_A_in_Italy/22587155）。